menu
    • menu
    [{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2\u00a0","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2\u00a0","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EB01","moa":"sPLA2\u00a0","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"Toll-like-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"EB06","moa":"CXCL-10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Velan Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Antibody","year":"2025","type":"Private Placement","leadProduct":"EB06","moa":"CXCL-10","graph1":"Dermatology","graph2":"Phase II","graph3":"Edesa Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Edesa Biotech \/ Velan Capital","highestDevelopmentStatusID":"8","companyTruncated":"Edesa Biotech \/ Velan Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Edesa Biotech

    Menu

    Edesa Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB06

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Velan Capital

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Edesa Biotech Secures $15M Private Placement Priced At-Market Under Nasdaq Rules

                            Details : The net proceeds from the offering will be used to fund the continued advancement of EB06, a CXCL10 monoclonal antibody, into a Phase 2 clinical study for patients with nonsegmental vitiligo.

                            Product Name : EB06

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 13, 2025

                            Lead Product(s) : EB06

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Velan Capital

                            Deal Size : $15.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa’s Paridiprubart Selected for U.S.-Funded Platform Trial in General ARDS

                            Details : EB05 (paridiprubart) is a TLR4 antagonists monoclonal antibody, which is being evaluated for the treatment of patients with acute respiratory distress syndrome.

                            Product Name : EB05

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            June 24, 2024

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB06

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

                            Details : EB06 is a monoclonal antibody which targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. It binds and inhibits CXCL10 as it is involved in initiation of the disease and the maintenance of vitiligo lesions.

                            Product Name : EB06

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 02, 2023

                            Lead Product(s) : EB06

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

                            Details : EB05 was developed to regulate the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure that accounts for ~10% of all ICU admissions.

                            Product Name : EB05

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            February 17, 2022

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Reports Favorable Mortality Reductions in COVID-19 Study

                            Details : EB05 is an experimental monoclonal antibody, announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study for treatment of hospitalized COVID-19 patients. Additional efficacy signals recorded in a broad range of mild to sever...

                            Product Name : EB05

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 19, 2021

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

                            Details : Positive results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.

                            Product Name : EB05

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            September 20, 2021

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

                            Details : EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.

                            Product Name : EB01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 03, 2021

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

                            Details : EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.

                            Product Name : EB01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2021

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy

                            Details : Edesa Biotech has received approval from the U.S. FDA and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical trial of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

                            Product Name : EB05

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 26, 2021

                            Lead Product(s) : Paridiprubart

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed

                            Edesa Biotech

                            Canada arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

                            Details : EB01, is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor met primary efficacy endpoint, which is the mean percent change from baseline on the CDSI at day 29.

                            Product Name : EB01

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 12, 2021

                            Lead Product(s) : EB01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth